Armata says diSArm study confirms efficacy of intravenous phage therapy for SAB

Armata Pharmaceuticals (ARMP) highlighted “positive” results from its recently completed Phase 2a diSArm study of AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia in a late-breaking oral presentation at IDWeek 2025. The Phase 2a study enrolled and dosed 42 patients, with 29 randomized to AP-SA02 in addition to BAT and 13 to placebo. Methicillin-resistant S. aureus was the causative pathogen in about 38% of both the AP-SA02 and placebo groups. Clinical response was assessed in the intent-to-treat population at Test of Cure on day 12, one week post-BAT, and End of Study four weeks after BAT completion. Safety analysis also included data from the Phase 1b portion of the trial. Day 12 clinical response rates were higher in the AP-SA02 group – 88% (21/24) versus 58% (7/12) in the placebo group as assessed by blinded site investigators, and 83% (20/24) in the AP-SA02 group versus 58% (7/12) in the placebo group as assessed by the blinded Adjudication Committee. “The results of the diSArm study confirm, for the first time in a randomized clinical trial, the efficacy of intravenous phage therapy for S. aureus bacteremia, and we are very pleased to highlight these compelling data in an oral presentation at IDWeek. The results of this rigorously designed study provide strong rationale for advancement into a Phase 3 superiority study that, if successful, would support its use in clinical practice for Staphylococcus aureus bacteremia. High-purity, phage-based therapeutics like AP-SA02 have the potential to become the new standard of care for this common, extremely severe, and often deadly infection,” stated Dr. Loren G. Miller, M.D., M.P.H., Professor of Medicine, David Geffen School of Medicine at UCLA, Chief, Division of Infectious Diseases at Harbor-UCLA Medical Center and the Lundquist Institute.